Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 11/20 | 0.40 |
| ▸ | DRD3 | P35462 | 7/20 | 0.40 |
| ▸ | DRD4 | P21917 | 6/20 | 0.40 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4945368 | 0.97 | HTR1A (0.41) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL4949934 | 0.96 | DRD2 (0.43) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL4950169 | 0.95 | DRD2 (0.43) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL4951276 | 0.94 | DRD2 (0.42) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL4952019 | 0.94 | DRD2 (0.41) | HTR1AHTR1DHTR1BSLC6A4DRD2 | |
| SCHEMBL4947482 | 0.88 | HTR1A (0.42) | HTR1ADRD2DRD3HTR2A | |
| SCHEMBL4945958 | 0.88 | DRD2 (0.49) | DRD2DRD3HTR2A | |
| SCHEMBL4950706 | 0.85 | HTR1A (0.41) | HTR1ADRD2DRD3DRD4HTR2A | |
| SCHEMBL4950371 | 0.84 | HTR1A (0.47) | HTR1ADRD2DRD3HTR2A | |
| SCHEMBL5512380 | 0.84 | DRD2 (0.57) | HTR1ASLC6A4DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | SCHWARZ PHARMA AG (DE) | 2008-08-14 | — | — | US | claimed |
| JP-2008526700-A | — | — | 2008-07-24 | — | — | JP | claimed |
| EP-1761524-B1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-11-21 | — | — | EP | claimed |
| EP-1761524-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2007-03-14 | — | — | EP | claimed |
| WO-2006072430-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2006-07-13 | — | — | WO | claimed |
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | SCHWARZ PHARMA AG (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1761524-B1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1761524-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006072430-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | DRD3, DRD2, DRD1 | HTR1A 206/4885HTR1D 108/4885HTR1B 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.